PE20050443A1 - Formulaciones farmaceuticas transdermicas - Google Patents
Formulaciones farmaceuticas transdermicasInfo
- Publication number
- PE20050443A1 PE20050443A1 PE2004001017A PE2004001017A PE20050443A1 PE 20050443 A1 PE20050443 A1 PE 20050443A1 PE 2004001017 A PE2004001017 A PE 2004001017A PE 2004001017 A PE2004001017 A PE 2004001017A PE 20050443 A1 PE20050443 A1 PE 20050443A1
- Authority
- PE
- Peru
- Prior art keywords
- formulation
- refers
- pharmaceutical formulations
- weight
- aqueous vehicle
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 2
- -1 OXIBUTININ Chemical compound 0.000 abstract 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 abstract 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 abstract 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 abstract 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-HQMMCQRPSA-N Ethanol-14C Chemical compound C[14CH2]O LFQSCWFLJHTTHZ-HQMMCQRPSA-N 0.000 abstract 1
- 239000008135 aqueous vehicle Substances 0.000 abstract 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 abstract 1
- 229960001736 buprenorphine Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229910052802 copper Inorganic materials 0.000 abstract 1
- 239000010949 copper Substances 0.000 abstract 1
- 229960005309 estradiol Drugs 0.000 abstract 1
- 229930182833 estradiol Natural products 0.000 abstract 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 abstract 1
- 229960002428 fentanyl Drugs 0.000 abstract 1
- 229940041616 menthol Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002687 nonaqueous vehicle Substances 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 238000005507 spraying Methods 0.000 abstract 1
- 229960003604 testosterone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA FORMULACION TRANSDERMICA QUE COMPRENDE a) UN AGENTE FARMACEUTICAMENTE ACTIVO SELECCIONADO DE ESTRADIOL, TESTOSTERONA, OXIBUTININA, BUPRENORFINA, FENTANILO; b) DE 0,1% A 5% EN PESO DE LA FORMULACION DE UN COPOLIMERO DE VP/VA Y c) UN VEHICULO ACUOSO SELECCIONADO DE ETANOL, ACETONA. LA FORMULACION CONTIENE ADEMAS UN AGENTE ANTINUCLEANTE SELECCIONADO DE POLIVINILPIRROLIDONA Y SE ENCUENTRA ENTRE 0,1% A 10% EN PESO DE LA FORMULACION; COMPRENDE TAMBIEN DE 0,1% A 0,5% DE UN INTENSIFICADOR COMO MENTOL, DIMETILSOSORBIDE, GLICERILMONO-OLEATO. SE REFIERE TAMBIEN A UN METODO PARA ADMINISTRAR UN AGENTE ACTIVO QUE COMPRENDE ROCIAR UNA FORMULACION TRANSDERMICA EN LA PIEL CARACTERIZADO PORQUE EL VEHICULO NO ACUOSO SE VOLATILIZA AL ENTRAR EN CONTACTO CON LA PIEL FORMANDO UNA PELICULA QUE COMPRENDE EL COPOLIMERO DE VP/VA Y EL AGENTE ACTIVO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1122MU2003 | 2003-10-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20050443A1 true PE20050443A1 (es) | 2005-06-14 |
Family
ID=34531861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2004001017A PE20050443A1 (es) | 2003-10-23 | 2004-10-22 | Formulaciones farmaceuticas transdermicas |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20070219171A1 (es) |
| EP (1) | EP1686969A1 (es) |
| JP (1) | JP2007509122A (es) |
| CN (1) | CN100431531C (es) |
| AP (1) | AP2006003628A0 (es) |
| AR (1) | AR046146A1 (es) |
| AU (1) | AU2004285335B2 (es) |
| BR (1) | BRPI0415725A (es) |
| CA (1) | CA2543245A1 (es) |
| IL (1) | IL175094A0 (es) |
| MA (1) | MA28167A1 (es) |
| MX (1) | MXPA06004460A (es) |
| NO (1) | NO20062234L (es) |
| NZ (1) | NZ547376A (es) |
| PA (1) | PA8615501A1 (es) |
| PE (1) | PE20050443A1 (es) |
| RU (1) | RU2006117527A (es) |
| SM (1) | SM200400022A (es) |
| SV (1) | SV2006001916A (es) |
| TW (1) | TW200524635A (es) |
| WO (1) | WO2005041943A1 (es) |
| ZA (1) | ZA200604036B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0518769D0 (en) * | 2005-09-14 | 2005-10-19 | Medpharm Ltd | Topical formulations |
| CA2719512A1 (en) | 2010-11-01 | 2012-05-01 | Stiefel Research Australia Pty Ltd | Polymeric topical compositions |
| CN102018671B (zh) * | 2011-01-05 | 2012-07-25 | 浙江大学 | 一种雌二醇透皮喷雾剂及其制备方法 |
| US20150065449A1 (en) * | 2011-08-12 | 2015-03-05 | Florida State University Research Foundation, Inc. | Treating Amyloidoses With A Vitamin B12 Composition Including Melatonin, Resveratrol, and EGCG |
| GB201200062D0 (en) | 2012-01-04 | 2012-02-15 | Innotesto Bvba | Estradiol oromucosal liquid compositions |
| TWI516281B (zh) * | 2014-07-16 | 2016-01-11 | 健維生技有限公司 | 改良之睪固酮製劑製法及所得之睪固酮製劑 |
| US20170296484A1 (en) * | 2015-11-23 | 2017-10-19 | Grace Therapeutics Llc | Topical Film-Forming Spray |
| WO2019140087A1 (en) * | 2018-01-10 | 2019-07-18 | Celista Pharmaceuticals Llc | Testosterone transdermal spray with film |
| EP3817731B1 (en) * | 2018-07-05 | 2025-09-03 | Celista Pharmaceuticals Llc | Testosterone and estradiol transdermal spray |
| CN112206222A (zh) * | 2018-11-09 | 2021-01-12 | 北京德默高科医药技术有限公司 | 含有布洛芬结构类似物的多层经皮给药系统 |
| CN115154661A (zh) * | 2022-07-29 | 2022-10-11 | 广州莱度品牌管理有限公司 | 一种仿生角质膜的制备方法 |
| CN118593475B (zh) * | 2024-06-06 | 2025-07-25 | 暨南大学 | 用于治疗帕金森病的组合物、鼻喷雾剂及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3868248D1 (de) * | 1987-05-27 | 1992-03-12 | Burghart Kurt | Transdermal therapeutisch wirkende pharmazeutische zubereitung sowie vorrichtung zum aufbringen der zubereitung. |
| FR2732223B1 (fr) * | 1995-03-30 | 1997-06-13 | Sanofi Sa | Composition pharmaceutique pour administration transdermique |
| FR2739031B1 (fr) * | 1995-09-27 | 1997-11-21 | Lhd Lab Hygiene Dietetique | Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique |
| IT1299566B1 (it) * | 1998-07-17 | 2000-03-16 | Ifi Istituto Farmacoterapico I | Cerotto transdermico e composizioni farmaceutiche comprendenti r (-)- norapropilapomorfina cloridrato e/o s (+) - norapropilapomorfina |
| ATE252380T1 (de) * | 1999-02-05 | 2003-11-15 | Cipla Ltd | Topische sprays enthaltend eine filmbildende zusammensetzung |
| US6962691B1 (en) * | 1999-05-20 | 2005-11-08 | U & I Pharmaceuticals Ltd. | Topical spray compositions |
| US6274167B1 (en) * | 2000-09-14 | 2001-08-14 | Vincent Margiotta | Topical anesthetic patch |
| US6528040B1 (en) * | 2001-01-18 | 2003-03-04 | Maurine Pearson | EMU oil-based formulations for use as an analgesic, anesthetic and antipruritic |
| DE10211832A1 (de) * | 2002-03-16 | 2003-10-02 | Lohmann Therapie Syst Lts | Hormonhaltiges transdermales therapeutisches System mit einem Wirkstoffreservoir auf der Basis von Vinylacetat-Vinylpyrrolidon-Copolymer mit verbesserter Kohäsion |
-
2004
- 2004-10-21 RU RU2006117527/15A patent/RU2006117527A/ru not_active Application Discontinuation
- 2004-10-21 BR BRPI0415725-7A patent/BRPI0415725A/pt not_active Application Discontinuation
- 2004-10-21 NZ NZ547376A patent/NZ547376A/xx not_active IP Right Cessation
- 2004-10-21 WO PCT/GB2004/004487 patent/WO2005041943A1/en not_active Ceased
- 2004-10-21 AP AP2006003628A patent/AP2006003628A0/xx unknown
- 2004-10-21 CA CA002543245A patent/CA2543245A1/en not_active Abandoned
- 2004-10-21 CN CNB2004800382138A patent/CN100431531C/zh not_active Expired - Fee Related
- 2004-10-21 EP EP04769002A patent/EP1686969A1/en not_active Withdrawn
- 2004-10-21 AU AU2004285335A patent/AU2004285335B2/en not_active Ceased
- 2004-10-21 ZA ZA200604036A patent/ZA200604036B/en unknown
- 2004-10-21 MX MXPA06004460A patent/MXPA06004460A/es unknown
- 2004-10-21 JP JP2006536176A patent/JP2007509122A/ja active Pending
- 2004-10-21 US US10/576,908 patent/US20070219171A1/en not_active Abandoned
- 2004-10-22 SM SM200400022A patent/SM200400022A/it unknown
- 2004-10-22 SV SV2004001916A patent/SV2006001916A/es not_active Application Discontinuation
- 2004-10-22 PA PA20048615501A patent/PA8615501A1/es unknown
- 2004-10-22 PE PE2004001017A patent/PE20050443A1/es not_active Application Discontinuation
- 2004-10-22 AR ARP040103859A patent/AR046146A1/es unknown
- 2004-10-22 TW TW093132292A patent/TW200524635A/zh unknown
-
2006
- 2006-04-23 IL IL175094A patent/IL175094A0/en unknown
- 2006-05-18 NO NO20062234A patent/NO20062234L/no not_active Application Discontinuation
- 2006-05-23 MA MA29045A patent/MA28167A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL175094A0 (en) | 2006-08-20 |
| KR20070000397A (ko) | 2007-01-02 |
| MXPA06004460A (es) | 2006-06-27 |
| BRPI0415725A (pt) | 2006-12-19 |
| PA8615501A1 (es) | 2005-10-25 |
| SM200400022B (it) | 2005-08-24 |
| CN1897927A (zh) | 2007-01-17 |
| WO2005041943A1 (en) | 2005-05-12 |
| RU2006117527A (ru) | 2007-12-10 |
| SV2006001916A (es) | 2006-03-16 |
| AP2006003628A0 (en) | 2006-06-30 |
| AR046146A1 (es) | 2005-11-23 |
| AU2004285335A1 (en) | 2005-05-12 |
| SM200400022A (it) | 2005-08-24 |
| AU2004285335B2 (en) | 2011-02-10 |
| HK1098351A1 (zh) | 2007-07-20 |
| NO20062234L (no) | 2006-06-30 |
| JP2007509122A (ja) | 2007-04-12 |
| MA28167A1 (fr) | 2006-09-01 |
| NZ547376A (en) | 2009-07-31 |
| CA2543245A1 (en) | 2005-05-12 |
| TW200524635A (en) | 2005-08-01 |
| US20070219171A1 (en) | 2007-09-20 |
| EP1686969A1 (en) | 2006-08-09 |
| CN100431531C (zh) | 2008-11-12 |
| ZA200604036B (en) | 2007-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2167061T3 (es) | Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino. | |
| HRP20060147B1 (hr) | Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu | |
| IL190838A0 (en) | Intranasal administration of rapid acting insulin | |
| AR046878A1 (es) | Agente endoparasiticida para administracion topica | |
| PE20050443A1 (es) | Formulaciones farmaceuticas transdermicas | |
| AR063201A1 (es) | Composiciones farmaceuticas de ropinirol y metodos de uso de las mismas | |
| CL2008002407A1 (es) | Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04). | |
| PT971705E (pt) | Formulacoes de farmacos de terapeutica de substituicao hormonal para aplicacao topica na pele | |
| PE20100265A1 (es) | Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion | |
| ES2088312T3 (es) | Formulacion de liberacion controlada que contiene tramadol. | |
| MX386614B (es) | Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo. | |
| AR032204A1 (es) | Complejos de inclusion de ciclodextrina-drospirenona | |
| AR044200A1 (es) | Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo | |
| PT1150686E (pt) | Matriz directamente compressivel para libertacao controlada de doses diarias unitarias de claritromicina | |
| ECSP066553A (es) | Formas de administración masticables, no comprimidas dosificadas individualmente. | |
| ECSP034915A (es) | Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion | |
| NO20083759L (no) | Doserings aerosoler for administrering av farmasoytiske preparater | |
| PA8549401A1 (es) | Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido | |
| AU2011219546B2 (en) | Fungal nail treatment composition | |
| AR046402A1 (es) | Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio | |
| ES2176786T3 (es) | Uso de extractos de ginkgo biloba para la preparacion de composicionesfarmaceuticas. | |
| BRPI0606373A2 (pt) | composição de xarope compreendendo dexibuprofeno como ingrediente ativo e método para a preparação da mesma | |
| PL1771180T3 (pl) | Kompozycja w postaci sprayu zawierająca kombinację propionianu klobetazolu i kalcytriolu, fazę alkoholową i fazę olejową | |
| AR086252A1 (es) | Formulacion topica que comprende dipropionato de beclometasona como ingrediente activo | |
| AR005730A1 (es) | Forma de fanciclovir, procedimiento para prepararla, composiciones farmaceuticas que la contienen y metodo para el tratamiento o profilaxis deinfecciones virales y el uso de dicha forma -fanciclovir monoidrato. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |